Thomas Auchincloss - Concert Pharmaceuticals Director
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
Director
Mr. Thomas G. Auchincloss Jr., is an Independent Director of Concert Pharmaceuticals Inc. Mr. Auchincloss is the Director of the Company. effective December 9, 2014. Since October 2013, Mr. Auchincloss has served as Managing Partner at Counterpoint Trading Company, LLC, a private investment firm. From August 2007 through September 2013, Mr. Auchincloss was selfemployed in private investing. From May 2005 to August 2007, Mr. Auchincloss worked as Chief Financial Officer of Metabolix, Inc., a public biomaterials company. Prior to that, Mr. Auchincloss served as a consultant with Metabolix, from April 2002 to May 2005, providing business development, financial and strategic consulting services. From 1994 to 2001, Mr. Auchincloss served in a variety of positions at Vertex Pharmaceuticals Incorporated, most recently as Vice President, Finance and Treasurer since 2017.
| Age | 56 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 781 860 0045 |
| Web | https://www.concertpharma.com |
Concert Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3853) % which means that it has lost $0.3853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0868) %, meaning that it created substantial loss on money invested by shareholders. Concert Pharmaceuticals' management efficiency ratios could be used to measure how well Concert Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 14.51 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Concert Pharmaceuticals has a current ratio of 9.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Concert Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Concert Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Concert Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Concert to invest in growth at high rates of return. When we think about Concert Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Chris Rollinson | WPP PLC ADR | N/A | |
| Londa Dewey | WPP PLC ADR | 53 | |
| Solomon Trujillo | WPP PLC ADR | 67 | |
| Joanne Wilson | WPP PLC ADR | 49 | |
| Ranjana Singh | WPP PLC ADR | N/A | |
| Keith Weed | WPP PLC ADR | 58 | |
| Paul Heath | WPP PLC ADR | N/A | |
| Fran CFA | WPP PLC ADR | N/A | |
| Nicole Seligman | WPP PLC ADR | 62 | |
| Angela Ahrendts | WPP PLC ADR | 60 | |
| Thomas Stafford | NL Industries | 90 | |
| Geoffrey Wild | WPP PLC ADR | N/A | |
| Kim Anderson | WPP PLC ADR | N/A | |
| Terry Worrell | NL Industries | 69 | |
| Mary Tidlund | Valhi Inc | 63 | |
| Norman Edelcup | Valhi Inc | 78 | |
| John Harper | NL Industries | 59 | |
| John Steedman | WPP PLC ADR | N/A | |
| Jon Steel | WPP PLC ADR | N/A | |
| Sandrine Dufour | WPP PLC ADR | 54 | |
| John Rogers | WPP PLC ADR | N/A | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 |
Concert Pharmaceuticals Leadership Team
Elected by the shareholders, the Concert Pharmaceuticals' board of directors comprises two types of representatives: Concert Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concert. The board's role is to monitor Concert Pharmaceuticals' management team and ensure that shareholders' interests are well served. Concert Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concert Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meghan FitzGerald, Director | ||
| Marc Becker, Chief Officer | ||
| Richard Aldrich, Chairman of the Board, Co-Founder | ||
| Scott Weintraub, Vice President - Commercial and Product Strategy | ||
| Ian Silverman, Senior Vice President and General Counsel | ||
| Wendall Wierenga, Director | ||
| Jeffrey Munsie, Chief Sec | ||
| Roger Tung, Co-Founder, CEO and President and Director | ||
| Christine Heek, Director | ||
| Mba MBA, CoFounder Chairman | ||
| Ryan Lynch, Principal Financial Officer, Principal Accounting Officer | ||
| Wendell Wierenga, Director | ||
| Peter Hutt, Director | ||
| Ronald Barrett, Director | ||
| Nancy Stuart, Chief Officer | ||
| James Cassella, Senior Vice President chief development officer | ||
| Lynette Herscha, General Counsel, Secretary | ||
| Robert Silverman, Senior Vice President and General Counsel | ||
| Justine Koenigsberg, VP of Corporate Communications and Investor Relations | ||
| Nabil PharmD, VP Devel | ||
| Ryan Daws, CFO | ||
| Wilfred Jaeger, Director | ||
| Thomas Auchincloss, Director | ||
| Jesper Hoiland, Director | ||
| Christine Boisclair, Vice President - Regulatory Affairs | ||
| Helmut Schuhsler, Director |
Concert Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concert Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Shares Owned By Insiders | 3.77 % | |||
| Shares Owned By Institutions | 77.05 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Concert Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Concert Pharmaceuticals' short interest history, or implied volatility extrapolated from Concert Pharmaceuticals options trading.
Pair Trading with Concert Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Concert Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Concert Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Concert Stock
| 0.64 | WINVU | WinVest Acquisition Corp | PairCorr |
Moving against Concert Stock
| 0.66 | PME | Pingtan Marine Enterprise | PairCorr |
| 0.64 | RMGCU | RMG Acquisition Corp | PairCorr |
| 0.58 | MCD | McDonalds Earnings Call This Week | PairCorr |
| 0.54 | INTC | Intel Earnings Call Next Week | PairCorr |
The ability to find closely correlated positions to Concert Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Concert Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Concert Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Concert Pharmaceuticals to buy it.
The correlation of Concert Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Concert Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Concert Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Concert Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Concert Pharmaceuticals information on this page should be used as a complementary analysis to other Concert Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |